Figure S9 from CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer

Q: What type of study is this?

This is a Experimental Study study.

Nikola Knoll; Sarah Masser; Blanka Bordas; Richard Y. Ebright; Guangyan Li; Devishi Kesar; Eliana Destefanis; Nicholas Kania; Diego J. Rodriguez; Jayu Jen; Sydney E. Zagar; Caleb Mensah; Zixin Chen; Samuel J. Moffitt; Erhumuoghene M. Enakireru; Yao He; Baomou Feng; Mira K. Chokshi; Cyrus Y. Jin; Srivatsan Raghavan; William R. Sellers; Kathleen M. Mulvaney

doi:10.1158/0008-5472.30125721

Key Points

Combination treatment of MEK1/2 inhibitor trametinib and PRMT5 inhibitor MRTX1719 improves colony formation in cancer cell lines.
Assays demonstrate significant effects across various drug concentrations for the tested combinations.
Colony formation assays reveal critical insights into effective cancer treatments for cells lacking the MTAP gene.
Findings underscore the potential for using combined therapies in targeting specific cancer types.

Implication

Combinatorial screening reveals effective treatments in MTAP-deleted cancer, highlighting the roles of MEK1/2 and PRMT5 inhibitors.

Abstract

Figure S9. Colony formation assays of five cell lines treated with MEK1/2 inhibitor trametinib, PRMT5 inhibitor MRTX1719, or the combination across all drug concentrations are shown.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Knoll et al. (2025) studied this question.

synapsesocial.com/papers/68d4508931b076d99fa588db https://doi.org/10.1158/0008-5472.30125721

View at Publisher

Ask AI

Bookmark

Share

Figure S9 from CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Figure S9 from CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading